middle.news
Nexalis Therapeutics Advances Clinical Plans Despite Funding Setback
3:46pm on Tuesday 1st of September, 2026 AEST
•
Healthcare
Read Story
Nexalis Therapeutics Advances Clinical Plans Despite Funding Setback
3:46pm on Tuesday 1st of September, 2026 AEST
Key Points
Loss after tax rises 51.9% to $1.3 million
Linlithgow Family Office cancels $52.3m funding facility
Clinical trials for IRX-211 and IRX-616a temporarily suspended
Settlement deal converts $641,848 debt into options
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE